Xeltis, a commercial-stage MedTech company based in the Netherlands and the USA, developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue, has raised an additional €20.5 million in new funding. This funding was secured from new and existing shareholders. The round was led by
Rahul Raj 
Xeltis, a commercial-stage MedTech company based in the Netherlands and the USA, developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue, has raised an additional €20.5 million in new funding.
This funding was secured from new and existing shareholders. The round was led by new investor Horizon 3 Healthcare, with participation from the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders.
Eliane Schutte, Chief Executive Officer, Xeltis, said, “This fundraising not only enables us to bring our groundbreaking vascular access technology to more European patients, as we continue our successful commercial rollout, but also enables us to advance our aXess™ pivotal trial in the US, prepare for US market launch and continue our other exciting clinical programs, XABG and XPAD. We welcome our new investor Horizon 3 Healthcare and thank them, and our existing investors, for their confidence in Xeltis as we look to bring much-needed alternatives to patients.”
Founded in 2006, Xeltis develops implants that enable the natural creation of living and long-lasting vessels to address the limitations of current treatment options for the millions of patients requiring hemodialysis vascular access or cardiovascular replacements every year.
The company states that its proprietary Restorex® platform utilises an advanced polymer implant which is transformed into the patient’s own tissue before gradually being absorbed and leaving new, living vessels in place that support long-term clinical outcomes.
Its most advanced product aXess™, an implantable blood vessel for hemodialysis vascular access, has received CE Mark approval and is now being commercially deployed across Europe.
Xeltis aims to improve patient outcomes by enabling the creation of living vessels to reduce the need for repeat interventions and address significant unmet needs in vascular access. The company also notes that its technology has high potential to be applied to other major vascular and cardiovascular diseases.
“The data generated by Xeltis to date has been highly compelling and underscores the potential of aXess™ to transform the hemodialysis access landscape and improve patient outcomes. We are impressed by the company’s strong execution and rapid progress and are proud to support Xeltis as it advances aXess™ through US clinical development and European commercialisation, while continuing to expand its broader pipeline of transformative implants,” said Matt McNamara, Chief Investment Officer of Horizon 3 Healthcare.
This round builds on the €50 million secured in 2025 from the European Investment Bank (EIB) and existing shareholders, and supports Xeltis’ next phase of clinical, regulatory and commercial execution. In 2022, the company secured €15 million of fresh investment from Chinese firm Grand Pharma.
The company plans to use this capital to finalise the ongoing US pivotal trial of aXess™, its first-of-its-kind living vascular access solution for hemodialysis, and to prepare for FDA submission and US Go-To- Market.
The funding will also enable the European commercial rollout of aXess™, the upscaling of the company’s manufacturing capabilities, and the continued advancement of its XABG and XPAD programmes in the clinic.
The fundraising follows the recent announcement by Xeltis of the European launch of aXess™, with the successful treatment of the first commercial patient in Germany. Alongside European commercialisation, Xeltis continues enrollment in its US pivotal trial of aXess™, which now exceeds 50%.
